 CAMBRIDGE, Mass., Jan. 21, 2021 GLOBE NEWSWIRE -- Spero Therapeutics, Inc. Nasdaq: SPRO, a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that the United States Patent and Trademark Office USPTO has issued U.S. Patent No. 10,889,587, which is directed to a crystalline formulation of tebipenem HBr, Speros oral carbapenem in development for the treatment of complicated urinary tract infection cUTI and acute pyelonephritis AP. In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP. 